Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Glaukos Corp(GKOS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GKOS
10/14/2026: GKOS (3-star) is currently NOT-A-BUY. Pass it for now.
Glaukos Corporation is a specialized medical technology company known for its pioneering work in minimally invasive glaucoma surgery (MIGS) and eye health. Its primary strength lies in a robust portfolio of proprietary implants and a shift toward sustained-release pharmaceuticals like iDose TR. This offers a compelling long-term growth story, though the company faces risks from intense competition from larger medical device peers and the execution pressures of scaling new products. As a growth-oriented stock, it often exhibits significant price volatility based on clinical trial milestones rather than immediate profitability. Investors should focus on the continued market adoption of its core products and the success of its expanding pipeline in retinal health.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in a high-growth sector with a strong pipeline of innovative products targeting large patient populations. |
| Momentum investor | Strong fit while signal remains positive | The stock often reacts significantly to positive clinical data readouts and commercial launch milestones. |
| Value investor | Weak fit | Glaukos typically trades at high valuation multiples due to its high growth profile and lack of consistent net income. |
| Dividend investor | Weak fit | The company does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | High volatility associated with medical device companies and regulatory dependence makes it unsuitable for low-risk strategies. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is sensitive to clinical trial outcomes and competitive product news, leading to frequent price swings. |
| Valuation risk | Medium / high | Premium market multiples depend on continued high growth, which can be threatened by execution setbacks. |
| Competition risk (Large cap conglomerates) | High | Competitors like Alcon and JNJ have significantly more resources for marketing and price negotiation. |
| Business quality | Medium | While the technology is innovative, the company faces pressure to prove long-term commercial sustainability across multiple segments. |
| Dividend income | Low / none | There is no dividend income stream for shareholders. |
| Execution risk | Medium | Successful commercialization of new products like iDose TR is essential for future growth targets. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 35.86% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/14/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.76B USD | Price to earnings Ratio - | 1Y Target Price 199.31 |
Price to earnings Ratio - | 1Y Target Price 199.31 | ||
Volume (30-day avg) 940.9K shares | Beta 0.69 | 52 Weeks Range 73.16 - 191.62 | Updated Date 10/14/2026 |
52 Weeks Range 73.16 - 191.62 | Updated Date 10/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.26 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Glaucoma | iStent family of devices and iDose TR. | The primary revenue driver, selling surgical and drug-delivery solutions to treat glaucoma. |
| Corneal Health | Photrexa and corneal cross-linking devices. | A growing segment focused on treating progressive vision-threatening conditions. |
| Geography | Global sales, primarily North America, Europe, and Asia-Pacific. | Revenue is diversified globally, though North America remains the dominant market. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 1666.67 | Enterprise Value 8.87B | Price to Sales(TTM) 15.93 |
Enterprise Value 8.87B | Price to Sales(TTM) 15.93 | ||
Enterprise Value to Revenue 14.47 | Enterprise Value to EBITDA -57.89 | Shares Outstanding 58.98M | Shares Floating 56.83M |
Shares Outstanding 58.98M | Shares Floating 56.83M | ||
Percent Insiders 3.57 | Percent Institutions 105.41 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.